Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Norway Grants Marketing Authorization to Illuccix PSMA-PET Imaging Agent in Prostate Cancer

March 5th 2025

NOMA has approved the PET imaging agent for the identification of PSMA-positive lesions in patients with prostate cancer.

FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

March 4th 2025

The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.

Analyses Show Effects of Treatment, Patient Location on HRQOL in Bladder and Prostate Cancer

March 1st 2025

HRQOL results were evaluated in rural patients with bladder cancer and prostate cancer following ADT treatment and postoperative radiotherapy.

Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management

February 24th 2025

Pedro Barata, MD, discusses the expansion of radioligand therapies and the identification of novel targets beyond PSMA in prostate cancer.

Darolutamide Provides Clinical Benefits vs Other AR Inhibitors in Black and White Patients With nmCRPC

February 24th 2025

Darolutamide generated lower treatment discontinuation rates and longer MFS vs enzalutamide or apalutamide in both Black and White patients with nmCRPC.

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Darolutamide With ADT/Docetaxel Shows Reduced Risk of Death in mHSPC Irrespective of Age

February 23rd 2025

Darolutamide plus ADT and docetaxel demonstrated efficacy benefits in men with mHSPC regardless of whether they were younger or older than 75 years of age.

Real-World Analysis Reveals Gaps in HRR Testing and PARP Inhibitor Treatment in mCRPC

February 22nd 2025

Most patients with mCRPC included in a real-world study did not undergo HRR testing at the time of diagnosis.

Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC

February 21st 2025

Pivotal phase 3 trials are ongoing following data from a phase 1 study showing that adding mevrometostat to enzalutamide was safe and efficacious.

67Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PSMA+ mCRPC

February 20th 2025

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

Dr Oh on the Development of Targeted Therapies in Prostate Cancer

February 17th 2025

William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management

February 17th 2025

Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.

OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer

February 17th 2025

Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.

Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC

February 14th 2025

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.

Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer

February 14th 2025

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Dr Saad on the Efficacy of Darolutamide Plus ADT In Low and High Volume mHSPC

February 14th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.

Darolutamide Plus ADT Is Efficacious in mHSPC Regardless of Disease Volume

February 13th 2025

The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.

EBRT With or Without STAD Shows Improved 15-Year Survival in Prostate Cancer

February 13th 2025

Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.

Composite Gene Expression Score Shows Potential to Predict Bavdegalutamide Benefit in mCRPC

February 13th 2025

A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.

G-CSF Allows for Efficacious Dose of Docetaxel With ARASENS Regimen in mHSPC

February 13th 2025

G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.